heart transplantation

Summary

Summary: The transference of a heart from one human or animal to another.

Top Publications

  1. ncbi Allograft vasculopathy versus atherosclerosis
    Maziar Rahmani
    The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Providence Research Institute, Vancouver, British Columbia, Canada
    Circ Res 99:801-15. 2006
  2. ncbi Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection
    Susan Stewart
    International Society for Heart and Lung Transplantation, Addison, Texas, USA
    J Heart Lung Transplant 24:1710-20. 2005
  3. ncbi Molecular identification of Trypanosoma cruzi discrete typing units in end-stage chronic Chagas heart disease and reactivation after heart transplantation
    Juan Miguel Burgos
    Laboratorio de Biologia Molecular de la Enfermedad de Chagas, Instituto de Ingeniería Genética y Biología Molecular, Universidad de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
    Clin Infect Dis 51:485-95. 2010
  4. ncbi Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience
    Kenji Kuwaki
    Transplantation Biology Research Center, Massachusetts General Hospital Harvard Medical School, MGH East, 13th Street, Boston, Massachusetts 02129, USA
    Nat Med 11:29-31. 2005
  5. ncbi Cardiac allograft vasculopathy: recent developments
    Daniel Schmauss
    Medizinische Klinik und Poliklinik I, University Hospital Munich Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
    Circulation 117:2131-41. 2008
  6. ncbi Novel small interfering RNA-containing solution protecting donor organs in heart transplantation
    Xiufen Zheng
    Department of Surgery, University of Western Ontario, London, Ontario, Canada
    Circulation 120:1099-107, 1 p following 1107. 2009
  7. ncbi International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010
    Mandeep R Mehra
    ISHLT Working Group on Classification of Cardiac Allograft Vasculopathy commissioned by the Education Committee and Board of Directors of the Society
    J Heart Lung Transplant 29:717-27. 2010
  8. ncbi Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation
    William S Harris
    Mid America Heart Institute, Saint Luke s Hospital, Kansas City, MO, USA
    Circulation 110:1645-9. 2004
  9. ncbi Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation
    Keith D Aaronson
    University of Michigan Medical Center, 1500 E Medical Center Dr, Cardiovascular Center, Room 2169, SPC 5853, Ann Arbor, MI 48109 5853, USA
    Circulation 125:3191-200. 2012
  10. ncbi Intrapulmonary ectopic liver after orthotopic heart transplantation
    Rupal I Mehta
    Department of Pathology and Laboratory Medicine, University of California Los Angeles, 10833 LeConte Ave, Los Angeles, CA 90095, USA
    Arch Pathol Lab Med 134:1060-2. 2010

Detail Information

Publications375 found, 100 shown here

  1. ncbi Allograft vasculopathy versus atherosclerosis
    Maziar Rahmani
    The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Providence Research Institute, Vancouver, British Columbia, Canada
    Circ Res 99:801-15. 2006
    Over the last 4 decades, heart transplantation (HTx) has evolved as a mainstream therapy for heart failure. Approximately half of patients needing HTx have organ failure consequent to atherosclerosis...
  2. ncbi Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection
    Susan Stewart
    International Society for Heart and Lung Transplantation, Addison, Texas, USA
    J Heart Lung Transplant 24:1710-20. 2005
    ..international grading system for cardiac allograft biopsies was adopted by the International Society for Heart Transplantation. This system has served the heart transplant community well, facilitating communication between transplant ..
  3. ncbi Molecular identification of Trypanosoma cruzi discrete typing units in end-stage chronic Chagas heart disease and reactivation after heart transplantation
    Juan Miguel Burgos
    Laboratorio de Biologia Molecular de la Enfermedad de Chagas, Instituto de Ingeniería Genética y Biología Molecular, Universidad de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina
    Clin Infect Dis 51:485-95. 2010
    ..Chronic Chagas heart disease (cChHD) is the most severe manifestation. Heart transplantation is the proper treatment for end-stage heart failure, although reactivation of disease may result after ..
  4. ncbi Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience
    Kenji Kuwaki
    Transplantation Biology Research Center, Massachusetts General Hospital Harvard Medical School, MGH East, 13th Street, Boston, Massachusetts 02129, USA
    Nat Med 11:29-31. 2005
    ..There were no infectious complications directly related to the immunosuppressive regimen. The transplantation of hearts from GalT-KO pigs increased graft survival over previous studies...
  5. ncbi Cardiac allograft vasculopathy: recent developments
    Daniel Schmauss
    Medizinische Klinik und Poliklinik I, University Hospital Munich Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
    Circulation 117:2131-41. 2008
    ..although there is still a need to confirm the impact of vasodilators in improving outcome after heart transplantation. Coronary revascularization for CAV is only palliative, with no long-term survival benefit...
  6. ncbi Novel small interfering RNA-containing solution protecting donor organs in heart transplantation
    Xiufen Zheng
    Department of Surgery, University of Western Ontario, London, Ontario, Canada
    Circulation 120:1099-107, 1 p following 1107. 2009
    ..Such manipulation of pathological gene expression may be performed by treatment of the graft ex vivo with small interfering RNA (siRNA) as part of the preservation procedure...
  7. ncbi International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010
    Mandeep R Mehra
    ISHLT Working Group on Classification of Cardiac Allograft Vasculopathy commissioned by the Education Committee and Board of Directors of the Society
    J Heart Lung Transplant 29:717-27. 2010
    ..This document represents a working formulation for an international nomenclature of cardiac allograft vasculopathy, similar to the development of the system for adjudication of cardiac allograft rejection by histology...
  8. ncbi Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation
    William S Harris
    Mid America Heart Institute, Saint Luke s Hospital, Kansas City, MO, USA
    Circulation 110:1645-9. 2004
    ..The extent of incorporation has not been determined in humans...
  9. ncbi Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation
    Keith D Aaronson
    University of Michigan Medical Center, 1500 E Medical Center Dr, Cardiovascular Center, Room 2169, SPC 5853, Ann Arbor, MI 48109 5853, USA
    Circulation 125:3191-200. 2012
    Contemporary ventricular assist device therapy results in a high rate of successful heart transplantation but is associated with bleeding, infections, and other complications...
  10. ncbi Intrapulmonary ectopic liver after orthotopic heart transplantation
    Rupal I Mehta
    Department of Pathology and Laboratory Medicine, University of California Los Angeles, 10833 LeConte Ave, Los Angeles, CA 90095, USA
    Arch Pathol Lab Med 134:1060-2. 2010
    ..woman who was found to have multiple intrapulmonary nodules detected on imaging 33 months after orthotopic heart transplantation. Needle biopsy of 2 discrete nodules showed benign hepatic tissue, consistent with intrapulmonary foci of ..
  11. ncbi Gene-expression profiling for rejection surveillance after cardiac transplantation
    Michael X Pham
    Stanford University Medical Center, Stanford, California, USA
    N Engl J Med 362:1890-900. 2010
    ..However, this procedure is uncomfortable, and there are risks associated with it. Gene-expression profiling of peripheral-blood specimens has been shown to correlate with the results of an endomyocardial biopsy...
  12. ncbi The technique for heterotopic cardiac transplantation in mice: experience of 3000 operations by one surgeon
    M Niimi
    Department of Surgery, Teikyo University, Tokyo, Japan
    J Heart Lung Transplant 20:1123-8. 2001
    ..The mouse heterotopic fully vascularized cardiac transplantation model has come into widespread use. However, the technique is still difficult. Therefore, simple anastomosis was introduced...
  13. ncbi Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation: a pre-experimental study
    A O Doesch
    Department of Cardiology, University of Heidelberg, Heidelberg, Germany
    Transplant Proc 42:4238-42. 2010
    ..This study evaluated patient adherence, as well as safety and efficacy among chronic stable heart transplantation (HT) patients switched from a conventional twice daily calcineurin inhibitor-based regimen (TAC or ..
  14. pmc Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation
    Enshi Wang
    State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, People s Republic of China
    J Cardiothorac Surg 8:165. 2013
    ..In this study, we monitored early myocardial injury and recovery after heart transplantation by detecting levels of circulating muscle-specific miR-133a, miR-133b and miR-208a.
  15. ncbi Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials
    Luit Penninga
    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Cochrane Hepato Biliary Group, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Eur J Clin Pharmacol 66:1177-87. 2010
    We conducted a systematic review of randomized trials to compare the benefits and harms of tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation.
  16. ncbi Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group
    Simon Maybaum
    Albert Einstein College of Medicine, Center for Advanced Cardiac Therapy, 3400 Bainbridge Ave, 7th Floor, Bronx, NY 10467 2490, USA
    Circulation 115:2497-505. 2007
    ..The LVAD Working Group Recovery Study was a prospective multicenter trial to assess the incidence of myocardial recovery in patients bridged to cardiac transplantation...
  17. ncbi Prognostic significance of delayed-enhancement magnetic resonance imaging: survival of 857 patients with and without left ventricular dysfunction
    Benjamin Y C Cheong
    Department of Diagnostic and Interventional Radiology, St Luke s Episcopal Hospital and the Texas Heart Institute, 6720 Bertner Ave, MC 2 270, Houston, TX 77030, USA
    Circulation 120:2069-76. 2009
    ..To date, relatively limited data are available on the prognostic value of DE-MRI, so we sought to determine whether DE-MRI findings independently predict survival...
  18. ncbi De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival
    J D Smith
    Transplant Immunology, Harefield Hospital, Imperial College, Harefield, UK
    Am J Transplant 11:312-9. 2011
    ..Early and regular monitoring of post-transplant DSA is required to identify patients at risk of allograft failure...
  19. pmc Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy
    Dilip S Nath
    Division of Cardiothoracic Surgery, Barnes Jewish Hospital, St Louis, Missouri, USA
    J Heart Lung Transplant 29:1277-85. 2010
    ..of acute antibody-mediated rejection (AMR) in the early post-transplant period (EP, <12 months) and cardiac allograft vasculopathy (CAV) in the late post-transplant period (LP, >12 months) after heart transplantation (HTx).
  20. ncbi Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation
    Michael Dandel
    Deutsches Herzzentrum Berlin, Department of Cardiothoracic and Vascular Surgery, Berlin, Germany
    Transpl Immunol 23:93-103. 2010
    ..improvement in post-transplant outcomes for all solid-organ transplants and, in particular, it allowed heart transplantation to emerge as a viable therapeutic option for patients with end-stage cardiac failure...
  21. ncbi Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation
    Sonja Guethoff
    DepDepartment of Cardiac Surgery, University of Munich, Marchioninistr 15, 81377 Munchen, Germany
    Transplantation 95:629-34. 2013
    ..combining tacrolimus (TAC) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart transplantation (HTX) are rarely published...
  22. pmc Identification and classification of acute cardiac rejection by intragraft transcriptional profiling
    Cecile T J Holweg
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Circulation 123:2236-43. 2011
    Treatment of acute rejection (AR) in heart transplantation relies on histopathological grading of endomyocardial biopsies according to International Society for Heart and Lung Transplantation guidelines...
  23. ncbi Antigens of persistent Chlamydia pneumoniae within coronary atheroma from patients undergoing heart transplantation
    Nicole Borel
    Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
    J Clin Pathol 65:171-7. 2012
    ..Current theory suggests that C pneumoniae may persist at the site of infection via an alternative replicative form, known as an aberrant body...
  24. ncbi Favorable short-term outcome of transplanted hearts selected from marginal donors by pharmacological stress echocardiography
    Tonino Bombardini
    Institute of Clinical Physiology, National Research Council, Pisa, Italy
    J Am Soc Echocardiogr 24:353-62. 2011
    ..The aim of this study was to establish the feasibility of an approach based on pharmacologic stress echocardiography as a gatekeeper for extended heart donor criteria...
  25. ncbi Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation
    M A Dew
    Department of Psychiatry, University of Pittsburgh School of Medicine and Medical Center, Pennsylvania 15213, USA
    J Heart Lung Transplant 18:549-62. 1999
    ..We prospectively examined whether a full range of compliance behaviors and psychiatric outcomes during the first year post-transplant predicted subsequent mortality and physical morbidity through 3 years post-transplant...
  26. ncbi Long-term prognosis of patients with Kawasaki disease complicated by giant coronary aneurysms: a single-institution experience
    Kenji Suda
    Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan
    Circulation 123:1836-42. 2011
    ..The aim of this study was to determine the long-term prognosis of patients with Kawasaki disease with giant aneurysms...
  27. ncbi Interleukin-17 accelerates allograft rejection by suppressing regulatory T cell expansion
    Satoshi Itoh
    Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA
    Circulation 124:S187-96. 2011
    ..However, the precise role in allograft rejection remains uncertain. In the present study, we investigated the role of IL-17 in acute allograft rejection using IL-17-deficient mice...
  28. ncbi Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy
    M R Mehra
    University of Maryland School of Medicine, Baltimore, Maryland, USA
    Am J Transplant 6:1248-56. 2006
    ..As the use of new assessment tools increases our understanding of this disease, better preventative and treatment strategies are evolving...
  29. pmc New insights on OX40 in the control of T cell immunity and immune tolerance in vivo
    Xiang Xiao
    Transplant Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Immunol 188:892-901. 2012
    ..Our data reveal a novel role for OX40 in promoting immune tolerance and may have important clinical implications...
  30. ncbi Chimerism of the transplanted heart
    Federico Quaini
    Department of Medicine, New York Medical College, Valhalla 10595, USA
    N Engl J Med 346:5-15. 2002
    ..The Y chromosome can be used to detect migrated undifferentiated cells expressing stem-cell antigens and to discriminate between primitive cells derived from the recipient and those derived from the donor...
  31. ncbi High dose of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts and generates regulatory cells
    Osamu Aramaki
    Department of Surgery, Nihon University, Tokyo, Japan
    Transplantation 75:217-20. 2003
    ..The authors investigated whether antithrombin III (AT-III) could induce unresponsiveness to alloantigens...
  32. ncbi Incidence of cancer after immunosuppressive treatment for heart transplantation
    Giovanbattista Ippoliti
    Divisione di Medicina Interna, Ospedale Civile, V Volturno 14, 27048 Voghera, Pavia, Italy
    Crit Rev Oncol Hematol 56:101-13. 2005
    ..In cardiac allograft recipients, intensive immunosuppression is frequently used to reverse acute rejection and the highest number of cardiac transplants was performed in the era of polypharmacy, usually consisting of triple therapy...
  33. ncbi alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months
    Yau Lin Tseng
    Transplantation Biology Research Center, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA
    Transplantation 80:1493-500. 2005
    ..The recent generation of alpha1,3-galactosyltransferase gene-knockout (GalT-KO) pigs has allowed investigation of the survival of GalT-KO pig organs in nonhuman primates...
  34. ncbi Selective cyclooxygenase 2 inhibitor induces indefinite survival of fully allogeneic cardiac grafts and generates CD4+ regulatory cells
    Takeshi Yokoyama
    Department of Surgery of Nihon University School of Medicine, Tokyo, Japan
    J Thorac Cardiovasc Surg 130:1167-74. 2005
    ..We investigated ability of a cyclooxygenase 2 inhibitor to inhibit alloimmune response in a murine cardiac transplantation model...
  35. ncbi Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial
    Anne Keogh
    St Vincent s Hospital, Xavier 4, Victoria St, Darlinghurst, Sydney, New South Wales 2010, Australia
    Circulation 110:2694-700. 2004
    ..Its effects on rejection and transplant vasculopathy in human heart transplant recipients are unknown...
  36. doi ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline
    Andrew E Epstein
    Circulation 117:e350-408. 2008
  37. ncbi Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients
    Aina Hognestad
    Department of Cardiology, Rikshospitalet, Oslo, Norway
    J Am Coll Cardiol 42:477-82. 2003
    ..levels of high-sensitivity C-reactive protein (hsCRP) and to examine whether an increase in hsCRP after heart transplantation predicts the development of CAV...
  38. ncbi Quality of life outcomes after heart transplantation in individuals bridged to transplant with ventricular assist devices
    M A Dew
    Department of Psychiatry, University of Pittsburgh School of Medicine and Medical Center, Pittsburg, Pennsylvania 15213, USA
    J Heart Lung Transplant 20:1199-212. 2001
    Increasing numbers of individuals receive ventricular assist devices (VADs) as bridges to heart transplantation. Physical morbidity risks and benefits, and quality of life (QOL) during VAD support have been documented...
  39. pmc Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection
    J A Diaz
    Department of Surgery, Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Am J Transplant 9:1773-83. 2009
    ..These observations reveal a new paradigm in which IL-6 drives development of pathologic hypertrophy and fibrosis in chronic cardiac allograft rejection and suggest that IL-6 could be a therapeutic target to prevent this disease...
  40. ncbi Whole blood genomic biomarkers of acute cardiac allograft rejection
    David Lin
    Department of Pathology and Laboratory Medicine, St Paul s Hospital University of British Columbia, Vancouver, British Columbia, Canada
    J Heart Lung Transplant 28:927-35. 2009
    ..In the Biomarkers in Transplantation initiative, we investigated gene expression profiles in peripheral blood of cardiac transplant subjects as potential biomarkers for diagnosis of allograft rejection...
  41. ncbi The effect of recipient cytokine gene polymorphism on cardiac transplantation outcome
    Ian S Gourley
    University of Pennsylvania Medical Center, Philadelphia, PA, USA
    Hum Immunol 65:248-54. 2004
    We determined the association between clinical outcomes after heart transplantation and gene polymorphism in five cytokines (tumor necrosis factor-alpha, transforming growth factor (TGF)-beta, interleukin-10, interleukin-6, and ..
  42. ncbi Limited utility of endomyocardial biopsy in the first year after heart transplantation
    Iman M Hamour
    Department of Cardiology, The Royal Brompton and Harefield NHS Trust, Harefield Hospital, Harefield, Middlesex UB9 6JH, United Kingdom
    Transplantation 85:969-74. 2008
    ..Protocols became standardized in an earlier era and their utility with contemporary immunosuppression has not been investigated...
  43. ncbi Transcriptional signals of T-cell and corticosteroid-sensitive genes are associated with future acute cellular rejection in cardiac allografts
    Mandeep R Mehra
    Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Heart Lung Transplant 26:1255-63. 2007
    ..Profiling mRNA levels of 11 informative genes expressed by circulating immune effector cells identifies cardiac allograft recipients at low risk for current moderate-severe acute cellular rejection (ACR)...
  44. ncbi Stem cell-derived cardiomyocytes after bone marrow and heart transplantation
    R A de Weger
    Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
    Bone Marrow Transplant 41:563-9. 2008
    ..The number of BM-derived cardiomyocytes in both BMT and HTX is not significantly different between the two types of transplantation and is at most 1%...
  45. ncbi Donor-transmitted coronary atherosclerosis
    Onnen Grauhan
    Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany
    J Heart Lung Transplant 22:568-73. 2003
    ..The purpose of this study is to evaluate to what extent native coronary atherosclerosis is transmitted through heart transplantation.
  46. ncbi Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat)
    Achim Koch
    Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
    J Heart Lung Transplant 24:708-13. 2005
    ..ATG) should induce effective immunosuppression, with a low rate of rejection in the initial phase after heart transplantation. Induction therapy with ATG allows post-operative renal recovery without the negative effects of highly ..
  47. ncbi Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection
    Katherine Lietz
    Cardiovascular Division, University of Minnesota, Minneapolis, USA
    Circulation 116:497-505. 2007
    ..In the present study, we describe outcomes of DT in the post-REMATCH era in the United States...
  48. ncbi Pre-transplant Toxoplasma gondii seropositivity among heart transplant recipients is associated with an increased risk of all-cause and cardiac mortality
    Satish Arora
    Department of Cardiology, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    J Am Coll Cardiol 50:1967-72. 2007
    ..gondii) seropositive heart transplant (HTx) recipients and the 4 donor/recipient seropairing groups...
  49. ncbi Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection
    Nermine Lila
    Laboratory for the Study of Cardiac Grafts and Prostheses, University of Pierre et Marie Curie, Broussais Hospital, Paris, France
    Circulation 105:1949-54. 2002
    ..In a preliminary study, we showed that HLA-G is expressed in the hearts of some patients after heart transplantation.
  50. pmc Molecular imaging of innate immune cell function in transplant rejection
    Thomas Christen
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:1925-32. 2009
    ..Yet, which macrophage functions may provide useful markers for detecting parenchymal rejection remains uncertain...
  51. ncbi Assessment of the potential heart donor: a role for biomarkers?
    Vamsidhar B Dronavalli
    Department of Cardiothoracic Surgery, Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham B15 2TH, United Kingdom
    J Am Coll Cardiol 56:352-61. 2010
    ..Cardiac troponins, cytokines, inflammatory markers, natriuretic peptides, and intracellular proteins may each have discriminant value. This review details the current status of biomarkers in the assessment of donor hearts...
  52. ncbi The fibrin-derived peptide Bbeta(15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model
    Dominik Wiedemann
    Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria
    Transplantation 89:824-9. 2010
    ..The purpose of this study was to investigate whether Bbeta(15-42) has a protective effect in cardiac allografts exposed to prolonged global ischemia and subsequent in vivo reperfusion...
  53. ncbi Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments
    Jun ichi Suzuki
    Department of Advanced Clinical Science and Therapeutics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Circ J 74:233-9. 2010
    ..The pathological and immunological characteristics of CAV and some promising methodologies for prevention of the disease are reviewed...
  54. ncbi Infection and malignancy after pediatric heart transplantation: the role of induction therapy
    Robert J Gajarski
    Division of Pediatric Cardiology, University of Michigan, CS Mott Children s Hospital, Ann Arbor, Michigan 48109, USA
    J Heart Lung Transplant 30:299-308. 2011
    ..This study hypothesized that induced pediatric patients would have an increased risk of these events compared with non-induced patients...
  55. ncbi Lung cancer after heart transplantation: results from a large multicenter registry
    M G Crespo-Leiro
    Hospital Universitario A Coruña, La Coruna
    Am J Transplant 11:1035-40. 2011
    In this study we analyzed Spanish Post-Heart-Transplant Tumour Registry data for adult heart transplantation (HT) patients since 1984. Median post-HT follow-up of 4357 patients was 6.7 years...
  56. ncbi Myocardial tissue engineering: toward a bioartificial pump
    Hidekazu Sekine
    Institute of Advanced Biomedical Engineering and Science, Tokyo Women s Medical University, 8 1 Kawada cho, Shinjuku ku, Tokyo, Japan
    Cell Tissue Res 347:775-82. 2012
    ..Cell sheet-based tissue engineering technologies therefore show an enormous promise as a novel approach in the field of myocardial tissue engineering...
  57. ncbi Effect of sympathetic reinnervation on cardiac performance after heart transplantation
    F M Bengel
    Nuklearmedizinische Klinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar, Germany
    N Engl J Med 345:731-8. 2001
    ..Late after cardiac transplantation, limited reinnervation of the transplanted heart may occur, but little is known about the effect of reinnervation on cardiac function and exercise performance...
  58. ncbi Exercise performance in patients with end-stage heart failure after implantation of a left ventricular assist device and after heart transplantation: an outlook for permanent assisting?
    N de Jonge
    Heart Failure and Heart Transplantation Unit, Heart Lung Center Utrecht, University Medical Center Utrecht, The Netherlands
    J Am Coll Cardiol 37:1794-9. 2001
    We sought to study exercise capacity at different points in time after left ventricular assist device (LVAD) implantation and subsequent heart transplantation (HTx).
  59. ncbi Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review
    Irmeli Lautenschlager
    Department of Virology, Helsinki University Hospital, and Helsinki University, Helsinki, Finland
    Transpl Int 25:493-502. 2012
    ..Treatment of HHV-6 is indicated in established end-organ disease such as encephalitis. Foscarnet, ganciclovir, and cidofovir have been used for treatment...
  60. ncbi Induction of alloimmune tolerance in heart transplantation through gene silencing of TLR adaptors
    X Zhang
    Departments of Surgery, Pathology, and Oncology, University of Western Ontario, London, Canada
    Am J Transplant 12:2675-88. 2012
    ..To our knowledge, this study is the first demonstration of prolonging the survival of allogeneic heart grafts through gene silencing of TLR signaling adaptors, highlighting the therapeutic potential of siRNA in clinical transplantation...
  61. pmc Transforming growth factor-beta polymorphisms and cardiac allograft rejection
    Raymond L Benza
    Division of Cardiovascular Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA
    J Heart Lung Transplant 28:1057-62. 2009
    ..Cytokine gene polymorphisms regulate cytokine expression. We analyzed transforming growth factor-beta (TGF-beta) allelic variation in codon 25 in susceptibility to acute rejection episodes in cardiac transplant recipients...
  62. pmc TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection
    Adam J Booth
    Division of Pulmonary and Critical Care, Department of Internal Medicine, University of Michigan Medical Center, 6240 MSRBIII 0624, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA
    Immunotherapy 2:511-20. 2010
    ..Further efforts to elucidate the interplay between these factors may direct the development of targeted therapies for this disease...
  63. ncbi Adoptive transfer of DNT cells induces long-term cardiac allograft survival and augments recipient CD4(+)Foxp3(+) Treg cell accumulation
    Zhu Xu Zhang
    The Multi Organ Transplant Program, London Health Sciences Centre, London, Ontario, Canada
    Transpl Immunol 24:119-26. 2011
    ..Our result suggests that allograft tolerance may require the co-existence of different type Treg cell phenotypes which are affected by current immunosuppression...
  64. ncbi Mannose-binding lectin deficiency offers protection from acute graft rejection after heart transplantation
    James E Fildes
    Transplant Centre, University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Manchester, UK
    J Heart Lung Transplant 27:1353-6. 2008
    ..However, the effects of MBL deficiency on acute rejection after heart transplantation are unknown. Ninety heart transplant recipients were included in this study...
  65. pmc Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model
    J Yang
    Transplantation Research Center, Renal Division, Brigham and Women s Hospital, Children s Hospital Boston, Harvard Medical School, Boston, MA, USA
    Am J Transplant 9:2837-44. 2009
    ....
  66. ncbi Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition
    Angela Montecalvo
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2582, USA
    J Immunol 180:3081-90. 2008
    ....
  67. ncbi Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance
    X Zhao
    Transplantation Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Am J Transplant 12:90-101. 2012
    ..Thus, targeting the effects of IL-6 production may represent an important part of costimulation blockade-based strategies to promote allograft acceptance and tolerance...
  68. ncbi Heart transplantation in the United States, 1999-2008
    M R Johnson
    University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Am J Transplant 10:1035-46. 2010
    This article features 1999-2008 trends in heart transplantation, as seen in data from the Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR)...
  69. ncbi Health-related quality of life and exercise tolerance in recipients of heart transplants and left ventricular assist devices: a prospective, comparative study
    Christiane Kugler
    Division of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
    J Heart Lung Transplant 30:204-10. 2011
    The aim of this study was to evaluate and compare health-related quality of life (HRQoL) and physical exercise tolerance in patients after heart transplantation (HTx) or implantation of a left ventricular assist device (LVAD).
  70. ncbi PPAR-γ signaling and IL-5 inhibition together prevent chronic rejection of MHC Class II-mismatched cardiac grafts
    Yan Chen
    Division of Pediatric Surgery, Department of Surgery, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, SAR
    J Heart Lung Transplant 30:698-706. 2011
    ....
  71. pmc Adiponectin inhibits allograft rejection in murine cardiac transplantation
    Yoshihisa Okamoto
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Transplantation 88:879-83. 2009
    ..This study investigated whether adiponectin modulates allograft rejection in major histocompatibility complex class II-mismatched cardiac transplants...
  72. ncbi Health-related quality of life after cardiac transplantation: results of a UK National Survey with Norm-based Comparisons
    Imran Saeed
    UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, UK
    J Heart Lung Transplant 27:675-81. 2008
    ..This study presents descriptive analyses of HRQOL and norm-based comparisons after cardiac transplantation in the UK...
  73. ncbi Cerebral blood flow in patients with chronic heart failure before and after heart transplantation
    N Gruhn
    Department of Medicine, Division of Cardiology, Rigshospitalet, University of Copenhagen, Denmark
    Stroke 32:2530-3. 2001
    ..Furthermore, we examined whether heart transplantation (n=5) could restore CBF...
  74. ncbi A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy
    Denise Hilfiker-Kleiner
    Department of Cardiology and Angiology, MHH, 30625 Hannover, Germany
    Cell 128:589-600. 2007
    ..Thus, a biologically active derivative of the pregnancy hormone prolactin mediates PPCM, implying that inhibition of prolactin release may represent a novel therapeutic strategy for PPCM...
  75. ncbi [Spanish Heart Transplantation Registry. 18th official report of the Spanish Society of Cardiology Working Group on Heart Failure, Heart Transplantation and Associated Therapies (1984-2006)]
    Luis Almenar-Bonet
    Sección de Insuficiencia Cardiaca, Trasplante Cardiaco y Otras Alternativas Terapéuticas, Sociedad Española de Cardiología, Madrid, Espana
    Rev Esp Cardiol 60:1177-87. 2007
    ..The purpose of this article was to report the results of heart transplantations (HTs) carried out in Spain from the first use of the technique until December 2006...
  76. ncbi Prolongation of survival of fully allogeneic cardiac grafts and generation of regulatory cells by a histamine receptor 2 antagonist
    Fumihiko Inoue
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Tokyo, Japan
    Transplantation 84:1288-97. 2007
    ..We examined whether the HR2 antagonist ranitidine affects the alloimmune response in a murine model of cardiac transplantation...
  77. ncbi Bicaval versus standard technique in orthotopic heart transplantation: a systematic review and meta-analysis
    Maike Schnoor
    Institute of Social Medicine, Medical University of Schleswig Holstein, Campus Luebeck, Luebeck, Germany
    J Thorac Cardiovasc Surg 134:1322-31. 2007
    We aimed to evaluate and compare the efficacy of the bicaval and the biatrial standard techniques in orthotopic heart transplantation.
  78. pmc Interleukin-17 promotes early allograft inflammation
    Victoria Gorbacheva
    Department of Immunology, The Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Pathol 177:1265-73. 2010
    ..Targeting the IL-17 signaling network in conjunction with other graft-prolonging therapies may decrease this injury and improve the survival of transplanted organs...
  79. ncbi Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors
    Helene Peche
    Institut National de la Sante et de la Recherche Medicale INSERM, Unit 437 and Institut de Transplantation et de Recherche en Transplantation ITERT, Nantes, Cedex 1 France
    Am J Transplant 5:255-67. 2005
    ..These data suggest that syngeneic aBMDCs can modulate immune responses...
  80. ncbi Posttraumatic stress disorder and depression in heart transplantation recipients: the relationship with outcome and adherence to medical treatment
    Angela Favaro
    Department of Neurosciences, University of Padua, Padova, Italy
    Gen Hosp Psychiatry 33:1-7. 2011
    There is growing evidence of the importance of psychiatric risk factors for predicting the outcome of heart transplantation (HT) recipients...
  81. ncbi Drawing networks of rejection - a systems biological approach to the identification of candidate genes in heart transplantation
    Martin Cadeiras
    Department of Medicine, Columbia University, New York, NY, USA
    J Cell Mol Med 15:949-56. 2011
    ..001, Fisher's exact test). Our results confirm the accuracy of ARACNe to reconstruct the PBMC transcriptional network and show the utility of systems biological approaches to identify possible molecular targets and biomarkers...
  82. ncbi Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model
    Elke Eggenhofer
    Department of Surgery, University Medical Center Regensburg, Regensburg, Germany
    Transpl Immunol 25:141-7. 2011
    ..Here, we focus on the immunoregulatory potential of combination therapies of MSCs and classic pharmacotherapy to mediate acceptance of solid organ grafts...
  83. pmc Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs
    Alberto Sanchez-Fueyo
    Liver Transplant Unit, Hospital Clinic Barcelona, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain
    Gastroenterology 140:51-64. 2011
    ..We review recently developed therapeutic strategies to promote tolerance to transplanted livers and other organs and diagnostic tools that might be used to identify patients most likely to accept or reject allografts...
  84. ncbi Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model
    Matthias Majetschak
    DeWitt Daughtry Family Department of Surgery, Divisions of Trauma and Surgical Critical Care Trauma Research and Cardiothoracic Surgery, University of Miami Miller School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
    Biochem Biophys Res Commun 365:882-8. 2008
    ..its regulation during cold ischemia-reperfusion is unknown, we evaluated the cardiac UPS in a model of heart transplantation in mice...
  85. pmc Second-opinion stress tele-echocardiography for the Adonhers (Aged donor heart rescue by stress echo) project
    Daniele Franchi
    Department of Echocardiography and Medical Informatics, Institute of Clinical Physiology, National Research Council, Via Moruzzi 1, Pisa 56124, Italy
    Cardiovasc Ultrasound 8:20. 2010
    ..This study aimed to verify feasibility of a "second opinion" of digitally transferred images of stress echo results to minimize technical variability in selection of aged donor hearts for heart transplant...
  86. pmc Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs
    Mary Amanda Dew
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Liver Transpl 14:159-72. 2008
    ..17-0.21). Future research should focus on improving the prediction of risk for substance use relapse, and on testing interventions to promote continued abstinence posttransplantation...
  87. ncbi A prospective, multicenter trial of the VentrAssist left ventricular assist device for bridge to transplant: safety and efficacy
    Donald Esmore
    The Alfred Hospital, Melbourne, Australia
    J Heart Lung Transplant 27:579-88. 2008
    ..The aim of this prospective, multicenter clinical trial was to determine the efficacy and safety of a third-generation LVAD, the VentrAssist, in a BTT cohort...
  88. ncbi Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation
    Hannah Zimmerman
    Department of Surgery, Section of Cardiothoracic Surgery, University of Arizona Health Sciences Center, University of Arizona, Tucson, Arizona 85724, USA
    Ann Thorac Surg 89:1211-7. 2010
    ..If maximal medical therapy fails, patients may then be treated with mechanical circulatory support devices and (or) cardiac transplantation. Our purpose is to demonstrate the long-term efficacy of these surgical interventions...
  89. ncbi Impaired endothelial progenitor cell recruitment may contribute to heart transplant microvasculopathy
    Elena Osto
    Department of Cardiology, University of Padova, Padova, Italy
    J Heart Lung Transplant 30:70-6. 2011
    ..in the pathogenesis of cardiac allograft vasculopathy, the leading cause of morbidity and mortality in heart transplantation (HTx)...
  90. ncbi Late reactivation of Chagas' disease presenting in a recipient as an expansive mass lesion in the brain after heart transplantation of chagasic myocardiopathy
    Paulo Euripedes Marchiori
    Department of Neurology, Sao Paulo University School of Medicine, Sao Paulo, Brazil
    J Heart Lung Transplant 26:1091-6. 2007
    ..In the last decades, millions of people from these countries have migrated to the United States, changing the scenario of acute Chagas' disease associated with blood transfusion in North America...
  91. ncbi The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database
    Mark J Russo
    Division of Cardiothoracic Surgery, Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, USA
    J Thorac Cardiovasc Surg 133:554-9. 2007
    ..1) To examine the interaction of donor age with ischemic time and their effect on survival and (2) to define ranges of ischemic time associated with differences in survival...
  92. pmc The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model
    Takuya Ueno
    Transplantation Research Center, Renal Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 118:742-51. 2008
    ..These studies define previously unknown functions of TIM-1 in regulating alloimmune responses in vivo and may provide a novel approach to promoting transplantation tolerance...
  93. ncbi The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells
    Meera J Nathan
    Department of Microbiology and Immunology, University of Michigan School of Medicine, Ann Arbor 48109, USA
    Am J Transplant 2:323-32. 2002
    ..They further point to a tissue specificity of this hyporesponsiveness, suggesting that not all donor alloantigen-reactive cells are subject to this regulation...
  94. ncbi Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation
    N Shulzhenko
    Department of Pediatrics, Escola Paulista de Medicina, , SP, Brazil
    Transplantation 72:1705-8. 2001
    ....
  95. ncbi Impact of TGFbeta1 gene polymorphisms on acute and chronic rejection in pediatric heart transplant allografts
    Sylvie Di Filippo
    Departments of Pediatrics, Surgery, and Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Transplantation 81:934-9. 2006
    ..The aim of this study was to assess the influence of IL-10 and TGFbeta1 gene polymorphisms on the development of acute rejection and coronary disease in pediatric heart transplant recipients...
  96. ncbi Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation
    Arnt E Fiane
    Department of Thoracic and Cardiovascular Surgery, Rikshospitalet University Hospital, N 0027 Oslo, Norway
    Eur Heart J 26:1660-5. 2005
    ..Transplant-associated coronary artery disease (TxCAD) is a major cause of post-transplant graft failure. The aim of this study was to investigate a possible role of mannose-binding lectin (MBL) deficiency and complement activation in TxCAD...
  97. ncbi Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; Implications for donor selection criteria
    Katherine Lietz
    Division of Cardiothoracic Surgery, Columbia Presbyterian Medical Center, Columbia University, New York, New York 10032, USA
    J Am Coll Cardiol 43:1553-61. 2004
    ..This study investigates the outcomes of cardiac transplantation using older donors...
  98. pmc Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment
    W C Aird
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02119, USA
    J Cell Biol 138:1117-24. 1997
    ..Taken together, the results suggest that the vWF gene is regulated by vascular bed-specific pathways in response to signals derived from the local microenvironment...
  99. ncbi Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation
    T J Dengler
    Department of Cardiology, Medical University Hospital, University of Heidelberg, Germany
    Transplantation 67:392-8. 1999
    ..Because this approach also inhibits a potentially tolerizing signal through CTLA-4, selective blockade of CD28 ligation might induce more profound immunosuppression and transplant tolerance...
  100. ncbi Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation
    O H Frazier
    Department of Cardiovascular Research, Texas Heart Institute, Houston, Tex 77225 0345, USA
    J Thorac Cardiovasc Surg 122:1186-95. 2001
    Despite advances in heart transplantation and mechanical circulatory support, mortality among transplant candidates remains high. Better ways are needed to ensure the survival of transplant candidates both inside and outside the hospital.
  101. ncbi Neuroendocrine profiling of humans receiving cardiac allografts
    Tsuneo Ogawa
    Cardiovascular Endocrinology Laboratory, University of Ottawa Heart Institute, Ontario, Canada
    J Heart Lung Transplant 24:1046-54. 2005
    Several studies have investigated changes in circulating hormones and markers of cardiac status after heart transplantation in humans...

Research Grants67

  1. Use of umbilical cord as a unique stem cell source for tissue regeneration
    Xiao Dong Chen; Fiscal Year: 2013
    ..Currently, the best option for completely restoring cardiac function after a large MI is heart transplantation. However, it is limited by donor availability and transplant rejection...
  2. Autoimmunity in the Mediation of Infectious Myocarditis
    Jay Reddy; Fiscal Year: 2013
    ..Patients affected with myocarditis can develop dilated cardiomyopathy (DCM), a common reason for heart transplantation, which to date is the only viable option for combating DCM...
  3. Self-Sensing Physiologic Control of a Rotary Mag Lev LVAD
    JAMES FARLEY WALTON; Fiscal Year: 2010
    ..While an estimated 40,000 congestive heart failure patients are candidates for heart transplantation, only 2,200 donor hearts are made available each year highlighting the need for mechanical circulatory ..
  4. Intravascular Cardiac Assist System for Decompression and Recovery
    CAITLYN J BOSECKER; Fiscal Year: 2010
    ..b>Heart transplantation can provide significant individual benefit, but its impact is limited by the number of donor organs ..
  5. Sphingosine 1 phosphate receptors 1 and 3 as novel targets in transplantation
    Amandeep Bajwa; Fiscal Year: 2013
    ..to induce an innate immune response after kidney IRI and lack of S1P3 prolongs graft survival in skin and heart transplantation studies...
  6. Quantification and Characterization of Coronary Atherosclerotic Plaque by CT
    Armin A Zadeh; Fiscal Year: 2013
    ..plaque volume and plaque characteristics compared to histopathology in 30 patients scheduled to undergo heart transplantation. This will be the first such study using current generation MDCT...
  7. Bioprocess for cardiac cell generation from human induced pluripotent stem cells
    EMMANOUHL TZANAKAKIS; Fiscal Year: 2013
    ..b>Heart transplantation is an effective therapeutic modality in reconstituting the function of damaged heart...
  8. Home ECG Monitoring to Detect Allograft Rejection Following Heart Transplantation
    Barbara J Drew; Fiscal Year: 2013
    ..technology for detection of donor organ (allograft) 3 rejection to improve patient outcomes following heart transplantation. The specific goal of this study is to 4 determine whether daily monitoring of the transplant recipient&..
  9. HCMR Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
    Stefan Neubauer; Fiscal Year: 2013
    ..HF death), aborted SCD (appropriate discharge of an implantable cardioverter-defibrillator), and need for heart transplantation. Secondary endpoints include all- cause mortality, ventricular tachyarrhythmias, hospitalization for heart ..
  10. Genome Transplant Dynamics: non-invasive sequencing-based diagnosis of rejection
    HANNAH AUGUSTA contact VALANTINE; Fiscal Year: 2010
    ..for detection of clinical events (acute rejection, chronic rejection, and graft dysfunction) after heart transplantation. We will conduct a prospective cohort study of 110 consecutive heart transplant recipients, collecting ..
  11. Molecular Imaging of Resident Cardiac Stem Cells
    Joseph C Wu; Fiscal Year: 2010
    ..For now, heart transplantation is the only viable treatment option for end-stage heart failure patients...
  12. Noninvasive Monitoring of In Situ Oxygenation and Cell Therapy in Infarct Heart
    Periannan Kuppusamy; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Heart disease is the leading cause of death in the United States. Heart transplantation is the only clinically effective therapy for end-stage heart failure, but it is available to only a few ..
  13. Molecular Imaging of Cardiac Stem Cell Therapy
    Joseph C Wu; Fiscal Year: 2013
    ..For now, heart transplantation is the only viable treatment option for end-stage heart failure patients...
  14. Chronic Graft Destruction: Interplay of Allo- and Autoantibodies and Nonadherence
    Steven A Webber; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Heart transplantation remains a palliative therapy with few recipients achieving survival beyond 20 years...
  15. Percutaneous deliverable biomaterial for treating myocardial infarction
    Adam M Kinsey; Fiscal Year: 2011
    ..There is a critical need to develop new therapies since end-stage heart failure is only treated through heart transplantation or left ventricular (LV) assist devices, and current pharmaceutical regimens do not adequately prevent ..
  16. Integrated Strategies for Novel Treatment of Myocardial Ischemia
    Joseph C Wu; Fiscal Year: 2013
    ..symptoms requiring more aggressive measures such as left ventricular assist device (LVAD) or orthotopic heart transplantation (OHT)...
  17. Individualizing Therapy for Kidney and Heart Transplant Recipients
    PETER SCOTT HEEGER; Fiscal Year: 2013
    ..The study will test the hypothesis that desensitization will lower PRA, diminish the waiting time to heart transplantation and result in acceptable 1 year graft survival and function...
  18. Sidenafil Impacts Exercise Performance in Adolescent Survivors of the Fontan
    Robert E Shaddy; Fiscal Year: 2013
    ..approximately 45% of predicted for age and gender;the risk of cardiopulmonary failure, death, or need for heart transplantation increases significantly...
  19. Imaging of Cardiac Transplant Rejection
    Matthias Nahrendorf; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Heart transplantation is often the only available therapeutic option in end-stage heart disease...
  20. Alloantibodies in Cardiac Transplantation - Intervention, Outcomes and Mechanisms
    Steven A Webber; Fiscal Year: 2012
    ..studies and should lead to important new knowledge about antibody mediated graft injury in pediatric heart transplantation. It should provide much needed information for the design of future clinical trials in this field...
  21. Scalable bioprocess for cardiomyocyte generation from human embryonic stem cells
    EMMANOUHL TZANAKAKIS; Fiscal Year: 2009
    ..b>Heart transplantation is an effective therapeutic modality in reconstituting the function of damaged heart...
  22. The Role of T cells and Macrophages in Cardiac Transplant Rejection
    Susan D Moffatt Bruce; Fiscal Year: 2010
    ..Aim 3 will be the translation of the findings from Aim 1 and 2 into human clinical heart transplantation whereby the role of macrophage-T cell interaction in promoting acute and chronic allograft injury will be ..
  23. Phase II: Percutaneous deliverable biomaterial for treating myocardial infarction
    Adam M Kinsey; Fiscal Year: 2013
    ..There is a critical need to develop new therapies since end-stage heart failure is only treated through heart transplantation or left ventricular (LV) assist devices, and current pharmaceutical regimens do not adequately prevent ..
  24. Autophagy, Adenosine and Pyruvate Protection During Heart Surgery
    Robert M Mentzer; Fiscal Year: 2012
    ..of morbidity and mortality after percutaneous coronary interventions (PCI), reparative heart surgery, and heart transplantation. The objective of this project is to develop new therapies to increase the heart's tolerance to ..
  25. KLF4, myeloid development, and transplantation arteriosclerosis
    A K M KHYRUL WARA; Fiscal Year: 2010
    ..TAA) is the major cause of morbidity and death in recipients who survive more than one year after heart transplantation. The diffuse, concentric lesions of TAA represent a series of highly specific cellular and molecular ..
  26. Role of complement in brain death induced injury to donor hearts
    Stephen Tomlinson; Fiscal Year: 2010
    Brain death (BD) and ischemia reperfusion injury (IRI) are unavoidable consequences of heart transplantation. Brain death produces profound physiologic derangements and the systemic effects of this central injury, although little ..
  27. Restoring LV Function Post-MI Using Fibrin-Gel Based Engineered Myocardium
    Lauren D Black; Fiscal Year: 2012
    ..There are currently a number of therapies aimed at preventing or treating heart failure post-MI. Only heart transplantation replaces infarcted myocardium to restore heart function, but there is a paucity of donor hearts and the ..
  28. Intermountain Pediatric Heart Disease Research Center
    L Luann Minich; Fiscal Year: 2010
    ..In addition, some of these children develop end-stage heart disease and may be listed for heart transplantation, If panel reactive antibodies (PRA) are >10%, prospective cross matching is required, limiting the ..
  29. Optimizing Mixed-Chimerism for Heart Transplantation in Non-Human Primates
    JOREN C contact MADSEN; Fiscal Year: 2010
    The objective of this two-year project is to improve the outcome following heart transplantation by clarifying the mechanisms involved with the induction of donor-specific tolerance via the mixed chimerism approach...
  30. University of Montreal Cardiac Surgery Clinical Investigation Group
    LOUIS PAUL PERRAULT; Fiscal Year: 2013
    ..performs a large spectrum of open and minimally invasive coronary, valvular and aortic surgery as well as heart transplantation and implantable artificial heart program and emerging strength in cell therapy and seven new hybrid ..
  31. Synchronous Valveless Pulsatile Support Device for the Failing Heart
    RICHARD WARREN SMALLING; Fiscal Year: 2013
    ..Over 100,000 people in the US are diagnosed with end stage HF annually. Heart transplantation is performed in only 2% of these cases due to lack of available donor hearts...
  32. VIRTUAL TOOLS FOR CARDIAC VENTRICULAR REMODELING SURGERY
    JULIUS MATTEO GUCCIONE; Fiscal Year: 2013
    ..specific aims: (1) Using our MMPST, measure in-vivo regional myocardial contractility in patients before heart transplantation;(2) Measure ex-vivo regional myocardial contractility in skinned fiber preparation obtained from the ..
  33. Targeted, Highly Sensitive, Non-Invasive Cardiac Transplant Rejection Monitoring
    MICHAEL EDWARD MITCHELL; Fiscal Year: 2013
    ..S. alone. One year survival following heart transplantation has improved to over 90%;however, 10 year survival remains less than 60%...
  34. Expanding the Donor Pool for Heart Transplantation
    Carmelo A Milano; Fiscal Year: 2013
    ..s. ..
  35. Genetically-engineered pig organ transplantation into nonhuman primates
    DAVID KC COOPER; Fiscal Year: 2013
    ..immunosuppressive regimen in preventing the innate and adaptive immune responses after heterotopic heart transplantation (Tx) from (A) GE pigs and (B) GE/CIITA pigs, and to determine whether prevention of elicited xenoimmunity ..
  36. Generation of human myocardium from native ECM scaffolds and adult derived cells
    Harald C Ott; Fiscal Year: 2012
    ..The definitive treatment is heart transplantation;yet, donor organ shortage and the need for immunosuppression limit clinical impact and outcomes...
  37. Profiling Biobehavioral Responses to Mechanical Support in Advanced Heart Failure
    CHRISTOPHER SEAN LEE; Fiscal Year: 2013
    ..Fewer than 5% of these advanced HF patients are eligible for heart transplantation, and organ donations are extremely limited...
  38. Isolated Left Ventricular Restraint Therapy for Heart Failure
    Michael H Kwon; Fiscal Year: 2011
    ..Despite significant advances in medical therapy, there is little to definitively offer patients other than heart transplantation. Ventricular restraint therapy is a new non-transplant surgical treatment for heart failure in which the ..
  39. Clinical and Genetic Evaluation of Donors for Cardiac Transplantation
    KIRAN KAUR KHUSH; Fiscal Year: 2013
    ..Kiran Khush, an instructor in cardiology and heart transplantation at Stanford University, who is establishing herself as a young investigator studying donor evaluation for ..
  40. Development of Percutaneous DLC for Total Cavo-pulmonary Assistance
    Dongfang Wang; Fiscal Year: 2011
    ..PUBLIC HEALTH RELEVANCE: We are proposing to develop a percutaneous Cavopulmonary assistance system to bridge the patients with failing Fontan circulation for recovery, reconstructive surgery and heart transplantation.
  41. REACH: Research Empowerment for Adult Congenital Hearts
    David J Sahn; Fiscal Year: 2010
    ..death, complications during pregnancy, valve dysfunction, need for further surgery, heart failure, and heart transplantation are all common outcomes, sometimes not recognized in a timely manner...
  42. Genomics for Transplantation: Discovery and Biomarkers
    Daniel R Salomon; Fiscal Year: 2013
    ..3) translation of these discoveries to enhance the safety and efficacy of clinical practices in kidney and heart transplantation. All of us believe that the best of translational medicine is advanced by the best of basic research...
  43. Alemtuzumab and Regulatory T Cells for Heart Transplant Tolerance in Monkeys
    Angus W Thomson; Fiscal Year: 2013
    ..In each Aim, the Treg will be administered on day 21, after the initial T cell depletion and heart transplantation (day 0);immunosuppressive therapy will be tapered and discontinued at 3 months...
  44. VALIDATION OF HEARTSBREATH TEST FOR HEART TRANSPLANT REJECTION
    Michael Phillips; Fiscal Year: 2012
    ..DESCRIPTION (provided by applicant): The clinical problem: Approximately 3,500 people worldwide now undergo heart transplantation every year...
  45. Fifth International Conference on Pediatric Cardiac Devices
    Akif Undar; Fiscal Year: 2010
    ..machines and membrane oxygenators;pulsatile versus non-pulsatile perfusion;nanotechnology;pediatric heart transplantation;systemic inflammation during acute and chronic support;computational fluid dynamics;novel designs of ..
  46. Development of a Miniature Right Heart Support Device
    TREVOR ARNOULT SNYDER; Fiscal Year: 2013
    ..Current approaches to replacement include heart transplantation and blood pumps to provide mechanical circulatory support...
  47. Pediatric Heart Tranplantation: Transitioning to Adult Care
    Elfriede Pahl; Fiscal Year: 2013
    ..transition program focused on enhancing adherence) to improve outcomes for emerging adults who underwent heart transplantation as children and transition to adult care...
  48. Continuous Flow Ventricular Assist Device-Induced Platelet Dysfunction
    TREVOR ARNOULT SNYDER; Fiscal Year: 2013
    ..The only definitive therapy is heart transplantation, but that remains limited by number (2,200 donor heart available each year) and cost...
  49. Myofibril disassembly during neonatal heart muscle cell proliferation
    Bernhard Kuhn; Fiscal Year: 2013
    ..Currently, the only way to replace heart muscle cells, cardiomyocytes, is through heart transplantation. Regenerative therapies would transform the treatment of congenital heart disease and save many lives...
  50. NO Metabolic Control in Pregnancy
    Thomas Hintze; Fiscal Year: 2006
    ..a small but significant number of mothers go on to have a post-partum cardiomyopathy often leading to heart transplantation, perhaps when adjustments that occur during pregnancy do not regress after parturition...
  51. Minimally Invasive VAD for Treatment of Acute Right Heart Failure
    SCOTT C CORBETT; Fiscal Year: 2010
    ..hypertension, or heart attack, as well as in patients who have been treated with cardiopulmonary bypass, heart transplantation, or left heart mechanical circulatory support...
  52. ISCHEMIA-REPERFUSION INJURY AFTER LUNG TRANSPLANTATION
    Joel Cooper; Fiscal Year: 1991
    ..pulmonary fibrosis, double lung transplantation for emphysema and crystic fibrosis, and combined lung-heart transplantation for individuals with end-stage lung disease combined with irreversible right heart failure...
  53. PRESERVATION AND CARDIAC TRANSPLANT VASCULOPATHY
    David Pinsky; Fiscal Year: 2003
    ..In a murine model of heart transplantation, preliminary data show a direct correlation between extent of initial ischemic injury and the degree of ..
  54. IMAGING INTIMAL HYPERPLASIA, MYOCYTE HYPOXIA, NECROSIS
    Lynne Johnson; Fiscal Year: 2000
    ..proliferation is transplant arteriosclerosis which is the primary cause of death in patients after heart transplantation. Uptake of In-111 Z2D3 will also be investigated in a swine model of transplant arteriosclerosis produced ..
  55. Role of autoimmunity in transplant rejection
    Gilles Benichou; Fiscal Year: 2007
    ..proposal are to: 1) identify CM determinants and characterize T cells mediating CM autoimmunity post-heart transplantation and, 2) investigate the mechanism(s) by which alloresponse causes autoimmunity to CM in heart-transplanted ..
  56. Role of Host Dendritic Cells in Heart Transplant Vasculopathy
    Zhiliang Wang; Fiscal Year: 2007
    ..Here we propose a novel approach to analyze the role of recipient DC in the outcome of heart transplantation: we will restore defined subsets of DC to recipient mice with profound deficiencies in DC subsets as the ..
  57. Mentored Patient-Oriented Research Career Development Award
    Ruey Kang Chang; Fiscal Year: 2006
    ..Children with single ventricle after the Fontan operation and children after orthotopic heart transplantation (OHT) are among children with the lowest exercise capacity...
  58. Restoring LV Function Post-MI Using Fibrin-Gel Based Engineered Myocardium
    Lauren Black; Fiscal Year: 2009
    ..There are currently a number of therapies aimed at preventing or treating heart failure post-Mi. Only heart transplantation replaces infarcted myocardium to restore heart function, but there is a paucity of donor hearts and the ..
  59. BEDSIDE SYSTEM FOR COMBINED RNA AND PACIN HEART FAILURE
    Jeffrey Lacy; Fiscal Year: 2001
    ..Improved prognostic evaluation can also have a profound benefit by more accurately identifying patients who are suitable for heart transplantation and/or coronary artery bypass. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
  60. QIGONG THERAPY FOR HEART DEVICE PATIENTS
    LORRAINE MANCIET; Fiscal Year: 2001
    ..health and quality of life of patients attached to mechanical hearts or assist devices while awaiting heart transplantation. Qigon, an ancient Chinese exercise that involves active participation of the individual in the form of ..
  61. ENHANCED GLYCOLYSIS FOR HYPOTHERMIC HEART PRESERVATION
    Sufan Chien; Fiscal Year: 2003
    ..temperature and during hypothermia, 2) in hypothermic rabbit heart preservation, and 3) in rabbit and dog heart transplantation. Cardiomyocyte function, FDP uptake and metabolism, pyruvate dehydrogenase (PDH) activity, pyruvate and ..
  62. SMALL ARTIFICIAL HEARTS WITH MINIMUN THROMBOSIS
    Willem Kolff; Fiscal Year: 1990
    ..intends to eliminate the two most important impediments of the artificial heart as a bridge to donor heart transplantation in human patients today...
  63. Complement C1q Function in Allogeneic Transplantation
    Kenneth Christopher; Fiscal Year: 2009
    ..T cell responses? By application of in vivo cell trafficking via transgenic GFP mice to a murine model of heart transplantation in the absence of graft C1q, we will determine the effector function, activation, cytokine production and ..
  64. PARS inhibitor for cardiac allotransplantation
    Prakash Jagtap; Fiscal Year: 2002
    Immune-mediated rejection is the principal obstacle to the use of heart transplantation for the treatment of end-stage cardiac failure. Current immunosuppressive regimens have limited efficacy and are associated with substantial toxicity...
  65. TECHNOLOGIES TO IMPROVE THE UTILITY OF ANIMAL MODELS
    JUDITH GWATHMEY; Fiscal Year: 2000
    ..In addition, we will create three new valuable models of cardiovascular disease i.e. heterotopic heart transplantation non-working and working as well as a supraclavicular approach to aortic banding...
  66. Magnetic Resonance Measurement of Heart and Liver Iron
    Gary Brittenham; Fiscal Year: 2006
    ..and expertise at Columbia University, including the Hatch MR Research Center, active programs of liver and heart transplantation, the Iron Reference Laboratory, and the SQUID biosusceptometry facility where hundreds of patients with ..
  67. VASCULAR DISEASE IN HUMAN HEART TRANSPLANTATION
    Geraldine Miller; Fiscal Year: 2003
    ..is one of several terms that describe proliferative, neointimal lesions of coronary arteries following heart transplantation. As a leading cause of late death and graft failure, CAV remains a serious limitation to long-term success ..